TY - JOUR T1 - Spatial Inequities in COVID-19 Testing, Positivity, Confirmed Cases and Mortality in 3 US Cities: an Ecological Study JF - medRxiv DO - 10.1101/2020.05.01.20087833 SP - 2020.05.01.20087833 AU - Usama Bilal AU - Sharrelle Barber AU - Loni P. Tabb AU - Ana V. Diez-Roux Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/13/2020.05.01.20087833.abstract N2 - Background Preliminary evidence has shown inequities in COVID-19 related cases and deaths in the US.Objective We explored the emergence of spatial inequities in COVID-19 testing, positivity, confirmed cases, and mortality in New York City, Philadelphia, and Chicago during the first six months of the pandemic.Design Ecological, observational study at the zip code tabulation area (ZCTA) level from March to September 2020.Setting Chicago, New York City and Philadelphia.Participants All populated ZCTAs in the three cities.Measures Outcomes were ZCTA-level COVID-19 testing, positivity, confirmed cases, and mortality cumulatively through the end of September. Predictors were the CDC social vulnerability index and its four domains, obtained from the 2014-2018 American Community Survey. We examined the spatial autocorrelation of COVID-19 outcomes using global and local Moran’s I and estimated associations using spatial conditional autoregressive negative binomial models.Results We found spatial clusters of high and low positivity, confirmed cases and mortality, co-located with clusters of low and high social vulnerability. We also found evidence for the existence of spatial inequities in testing, positivity, confirmed cases and mortality for the three cities. Specifically, neighborhoods with higher social vulnerability had lower testing rates, higher positivity ratios, confirmed case rates and mortality rates.Limitations ZCTAs are imperfect and heterogeneous geographical units of analysis. We rely on surveillance data, which may be incomplete.Conclusion We found spatial inequities in COVID-19 testing, positivity, confirmed cases, and mortality in three large cities of the US.Registration N/AFunding source NIH (DP5OD26429) and RWJF (77644)Competing Interest StatementThe authors have declared no competing interest.Funding StatementUB was supported by the Office of the Director of the National Institutes of Health under award number DP5OD26429. UB, SB, and ADR were also supported by the Robert Wood Johnson Foundation under award number 77644. The funding sources had no role in the analysis, writing or decision to submit the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data is publicly available and deidentified.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is publicly available. Code is available on a github repository. https://github.com/usamabilal/COVID_Disparities ER -